Kendrith Rowland
Research Subjects
Kendrith Rowland has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Alberto J. Montero
Case Western Reserve University
5 shared publications - Amy S. Clark
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA
5 shared publications - Antonio C. Wolff
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
5 shared publications - Carla Falkson
University of Rochester, Rochester, New York
5 shared publications - Elisa Krill-Jackson
University of Miami, Miami, Florida
5 shared publications - Fengmin Zhao
Dana-Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, Massachusetts
5 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Table 1. CONSORT Checklist.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Table 1. CONSORT Checklist.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Figure 1. CONSORT Diagram.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Figure 1. CONSORT Diagram.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Table 2. Representativeness of Study Participants.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Supplementary Table 2. Representativeness of Study Participants.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Data from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Purpose:Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + avelumab (Ave).Patients and Methods:Patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had progressed on at least one line of endocrine therapy with a cyclin-dependent kinase 4/6 inhibitor and had not received chemotherapy for metastatic breast cancer were eligible. Patients were randomized 1:1:1 to Pac, Pac/Pel, or Pac/Pel/Ave after a three-patient run-in confirmed safety of the triplet regimen. Response was assessed every 8 weeks until week 16 and then every 12 weeks using RECIST v1.1. The primary endpoint was 16-week ORR. Statistical comparison across arms was not planned.Results:Forty-eight patients were enrolled, with 45 randomized. The 16-week ORR was 20%, 31%, and 14% in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. The median progression-free survival was 6.4, 12.1, and 5.8 months in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. There were more adverse events, particularly infusion reactions, in the combination arms than the Pac arm. Expansion of peripheral T-cell clones was observed by cycle 4 in Pac/Pel but not the Pac or Pac/Pel/Ave arms.Conclusions:The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Purpose:Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + avelumab (Ave).Patients and Methods:Patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had progressed on at least one line of endocrine therapy with a cyclin-dependent kinase 4/6 inhibitor and had not received chemotherapy for metastatic breast cancer were eligible. Patients were randomized 1:1:1 to Pac, Pac/Pel, or Pac/Pel/Ave after a three-patient run-in confirmed safety of the triplet regimen. Response was assessed every 8 weeks until week 16 and then every 12 weeks using RECIST v1.1. The primary endpoint was 16-week ORR. Statistical comparison across arms was not planned.Results:Forty-eight patients were enrolled, with 45 randomized. The 16-week ORR was 20%, 31%, and 14% in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. The median progression-free survival was 6.4, 12.1, and 5.8 months in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. There were more adverse events, particularly infusion reactions, in the combination arms than the Pac arm. Expansion of peripheral T-cell clones was observed by cycle 4 in Pac/Pel but not the Pac or Pac/Pel/Ave arms.Conclusions:The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.
- Open Access
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (13) , 2655-2662
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Purpose: Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + avelumab (Ave). Patients and Methods: Patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had progressed on at least one line of endocrine therapy with a cyclin-dependent kinase 4/6 inhibitor and had not received chemotherapy for metastatic breast cancer were eligible. Patients were randomized 1:1:1 to Pac, Pac/Pel, or Pac/Pel/Ave after a three-patient run-in confirmed safety of the triplet regimen. Response was assessed every 8 weeks until week 16 and then every 12 weeks using RECIST v1.1. The primary endpoint was 16-week ORR. Statistical comparison across arms was not planned. Results: Forty-eight patients were enrolled, with 45 randomized. The 16-week ORR was 20%, 31%, and 14% in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. The median progression-free survival was 6.4, 12.1, and 5.8 months in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. There were more adverse events, particularly infusion reactions, in the combination arms than the Pac arm. Expansion of peripheral T-cell clones was observed by cycle 4 in Pac/Pel but not the Pac or Pac/Pel/Ave arms. Conclusions: The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.
- 29 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (13) , 2655-2662
Open AccessA Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Purpose: Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + avelumab (Ave). Patients and Methods: Patients with hormone receptor–positive, HER2-negative metastatic breast cancer who had progressed on at least one line of endocrine therapy with a cyclin-dependent kinase 4/6 inhibitor and had not received chemotherapy for metastatic breast cancer were eligible. Patients were randomized 1:1:1 to Pac, Pac/Pel, or Pac/Pel/Ave after a three-patient run-in confirmed safety of the triplet regimen. Response was assessed every 8 weeks until week 16 and then every 12 weeks using RECIST v1.1. The primary endpoint was 16-week ORR. Statistical comparison across arms was not planned. Results: Forty-eight patients were enrolled, with 45 randomized. The 16-week ORR was 20%, 31%, and 14% in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. The median progression-free survival was 6.4, 12.1, and 5.8 months in the Pac, Pac/Pel, and Pac/Pel/Ave arms, respectively. There were more adverse events, particularly infusion reactions, in the combination arms than the Pac arm. Expansion of peripheral T-cell clones was observed by cycle 4 in Pac/Pel but not the Pac or Pac/Pel/Ave arms. Conclusions: The addition of Pel to Pac was associated with increased toxicity, expanded peripheral T-cell clones, and numerically increased the ORR and progression-free survival compared with Pac; Pac/Pel/Ave further increased toxicity and blunted T-cell responses without obvious increase in efficacy. Investigation of the Pac/Pel combination warrants consideration with careful attention to acute toxicity.
- 14 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (8_Suppleme) , CT143
Abstract CT143: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer
Background: Bria-IMT (SV-BR-1-GM) is an off-the-shelf whole tumor cell therapeutic vaccine engineered to express class I & class II HLAs, secrete GM-CSF, and function as antigen-presenting cells; with subsequent enhancements improving in-vitro characteristics. By expressing cancer antigens such as HER2/Neu and PRAME, SV-BR-1-GM also serves as the reservoir of cancer antigens to activates patient’s anti-tumor immune responses. The safety and efficacy of the ongoing clinical trial of SV-BR-1-GM in combination with a PD1 inhibitor are reported. We also report post-hoc exploratory data for patients with advanced metastatic breast cancer (aMBC) treated with SV-BR-1-GM regimens. Methods: Ongoing prospective, phase 1-2, with an expansion randomized phase 2 cohort (NCT03328026; 2018-present) using SV-BR-1-GM with a PD1 inhibitor (pembrolizumab or retifanlimab) with cycles every 3 weeks (16 patients dosed to date). SV-BR-1-GM “monotherapy” (NCT03066947; 2013-8), a completed prospective phase 1-2 results are also presented. Results: A total of 51 patients received any SV-BR-1-GM regimen; 27 in monotherapy (SV) and 24 in combination with a PD-1 inhibitor (CO) currently ongoing: 4 subjects from SV continued on with CO. Median prior regimens = 5; 61% ER or PR+; 6% ER or PR-/HER2+ and 29% triple negative. SV-BR-1-GM was well tolerated. Disease control rate was 40% with SV and 41% with CO in subjects with available assessment(s). Median PFS was 2.7 months with 6 having PFS >150 days (150-226) for SV and 2.6 months with 5 > 150 days (188-308) for CO. Per protocol, 23 patients had anergy testing prior to treatment. Among those with a normal immunologic response (n=13, 56%), disease outcomes included 4 SD and 2 PR (46% CBR) vs anergic patients (n=7, 30%) with 1 SD (14% CBR); 3 patients (13%) with unknown anergy testing had 0% CBR. All 7 anergic patients developed delayed-type hypersensitivity (DTH) injection site responses to SV-BR-1-GM. Subjects with DTH (injection site induration/erythema) had a significant reduction in the risk of progression or death (HR=0.096, 95%CI:0.02-0.50, p6mo). TEAEs occurred in 20/24 (83%) of subjects in CO including 9/24 (38%) with injection site AEs. There were no AEs of special interest eg cytokine storm. There were no Grade 5 and only 6 grade 4 AEs in CO. Conclusions: In an ongoing randomized phase 2, anergic patients had worse outcomes. SV-BR-1-GM was able to illicit an immune response regardless. Responses, stable disease and CBR were seen and associated with immune responses including injection site erythema/induration (DTH), CTC changes and tumor grade I/II. Patients with disease control had better quality of life. SV-BR-1-GM may be able to alter an anergic immune system for clinical benefit. Future pivotal trials will be based upon the ongoing confirmatory randomized clinical trial. Citation Format: Saranya Chumsri, Minal Barve, Chaitali Nangia, Bonnie L. Guerin, Jarrod Holmes, Karim Mohammed, John Knecht, Shaker Dakhil, William V. Williams, Charles Wiseman, Mingjin Chang, Miguel Lopez-Lago, John G. Knecht, Kendrith Rowland, Ralph V. Boccia, Giuseppe Del Priore, Carmen Calfa. Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT143.
- 14 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (8_Suppleme) , CT143
Abstract CT143: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer
Background: Bria-IMT (SV-BR-1-GM) is an off-the-shelf whole tumor cell therapeutic vaccine engineered to express class I & class II HLAs, secrete GM-CSF, and function as antigen-presenting cells; with subsequent enhancements improving in-vitro characteristics. By expressing cancer antigens such as HER2/Neu and PRAME, SV-BR-1-GM also serves as the reservoir of cancer antigens to activates patient’s anti-tumor immune responses. The safety and efficacy of the ongoing clinical trial of SV-BR-1-GM in combination with a PD1 inhibitor are reported. We also report post-hoc exploratory data for patients with advanced metastatic breast cancer (aMBC) treated with SV-BR-1-GM regimens. Methods: Ongoing prospective, phase 1-2, with an expansion randomized phase 2 cohort (NCT03328026; 2018-present) using SV-BR-1-GM with a PD1 inhibitor (pembrolizumab or retifanlimab) with cycles every 3 weeks (16 patients dosed to date). SV-BR-1-GM “monotherapy” (NCT03066947; 2013-8), a completed prospective phase 1-2 results are also presented. Results: A total of 51 patients received any SV-BR-1-GM regimen; 27 in monotherapy (SV) and 24 in combination with a PD-1 inhibitor (CO) currently ongoing: 4 subjects from SV continued on with CO. Median prior regimens = 5; 61% ER or PR+; 6% ER or PR-/HER2+ and 29% triple negative. SV-BR-1-GM was well tolerated. Disease control rate was 40% with SV and 41% with CO in subjects with available assessment(s). Median PFS was 2.7 months with 6 having PFS >150 days (150-226) for SV and 2.6 months with 5 > 150 days (188-308) for CO. Per protocol, 23 patients had anergy testing prior to treatment. Among those with a normal immunologic response (n=13, 56%), disease outcomes included 4 SD and 2 PR (46% CBR) vs anergic patients (n=7, 30%) with 1 SD (14% CBR); 3 patients (13%) with unknown anergy testing had 0% CBR. All 7 anergic patients developed delayed-type hypersensitivity (DTH) injection site responses to SV-BR-1-GM. Subjects with DTH (injection site induration/erythema) had a significant reduction in the risk of progression or death (HR=0.096, 95%CI:0.02-0.50, p6mo). TEAEs occurred in 20/24 (83%) of subjects in CO including 9/24 (38%) with injection site AEs. There were no AEs of special interest eg cytokine storm. There were no Grade 5 and only 6 grade 4 AEs in CO. Conclusions: In an ongoing randomized phase 2, anergic patients had worse outcomes. SV-BR-1-GM was able to illicit an immune response regardless. Responses, stable disease and CBR were seen and associated with immune responses including injection site erythema/induration (DTH), CTC changes and tumor grade I/II. Patients with disease control had better quality of life. SV-BR-1-GM may be able to alter an anergic immune system for clinical benefit. Future pivotal trials will be based upon the ongoing confirmatory randomized clinical trial. Citation Format: Saranya Chumsri, Minal Barve, Chaitali Nangia, Bonnie L. Guerin, Jarrod Holmes, Karim Mohammed, John Knecht, Shaker Dakhil, William V. Williams, Charles Wiseman, Mingjin Chang, Miguel Lopez-Lago, John G. Knecht, Kendrith Rowland, Ralph V. Boccia, Giuseppe Del Priore, Carmen Calfa. Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT143.
- Open Access
- 24 June 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2548-2554
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
Based on preclinical studies, the vascular endothelial pathway is an important mechanism for estrogen receptor resistance. We conducted a phase II study of fulvestrant and bevacizumab in patients with aromatase inhibitor pretreated metastatic breast cancer. A single-stage phase II study was conducted with these objectives: 6-month progression-free survival (PFS), tumor response, toxic effect, and overall survival. Regimen: 250 mg fulvestrant days 1 and 15 (cycle 1) then day 1 (cycle 2 and beyond) and 10 mg/kg bevacizumab days 1 and 15 of each 4-week cycle. At interim analysis, 20 eligible patients initiated treatment, 11 were progression free and on treatment at 3 months, not meeting the protocol-specified efficacy requirements (at least 12 of 20). Accrual remained open during interim analysis with 36 patients enrolling before final study closure. Among the 33 eligible patients, the median PFS was 6.2 months [95% confidence interval (CI) 3.6–10.1 months]. Of the 18 with measurable disease, 4 (22%) patients (95% CI 6% to 48%) had a confirmed tumor response (1 complete, 3 partial). The most common grade 3/4 adverse events were hypertension 3 (9%) and headache 3 (9%). The fulvestrant/bevacizumab combination is safe and tolerable; however, it did not meet its statistical end point.
- 24 June 2013
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2548-2554
Open AccessN0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
Based on preclinical studies, the vascular endothelial pathway is an important mechanism for estrogen receptor resistance. We conducted a phase II study of fulvestrant and bevacizumab in patients with aromatase inhibitor pretreated metastatic breast cancer. A single-stage phase II study was conducted with these objectives: 6-month progression-free survival (PFS), tumor response, toxic effect, and overall survival. Regimen: 250 mg fulvestrant days 1 and 15 (cycle 1) then day 1 (cycle 2 and beyond) and 10 mg/kg bevacizumab days 1 and 15 of each 4-week cycle. At interim analysis, 20 eligible patients initiated treatment, 11 were progression free and on treatment at 3 months, not meeting the protocol-specified efficacy requirements (at least 12 of 20). Accrual remained open during interim analysis with 36 patients enrolling before final study closure. Among the 33 eligible patients, the median PFS was 6.2 months [95% confidence interval (CI) 3.6–10.1 months]. Of the 18 with measurable disease, 4 (22%) patients (95% CI 6% to 48%) had a confirmed tumor response (1 complete, 3 partial). The most common grade 3/4 adverse events were hypertension 3 (9%) and headache 3 (9%). The fulvestrant/bevacizumab combination is safe and tolerable; however, it did not meet its statistical end point.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 3506
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU
3506 Background: Single agent CPT-11 is indicated as standard treatment (Rx) for pts with CRC who failed prior 5FU based Rx. FOLFOX4 is active as 1st and 2nd line Rx of CRC. The primary goal of this trial was to determine whether overall survival (OS) of pts treated with 2nd line CPT-11 (Arm A) was equivalent to Rx with 2nd line FOLFOX4 (Arm B). Pts were to cross-over to the other Rx after 2nd line failure. Methods: Eligible pts had failed one prior 5FU based Rx, either for metastatic disease or ≤ 6 months of adjuvant 5FU Rx. Initial protocol Rx (doses in mg/m2) for Arm A: CPT-11 350 d1 q3w (300 for ECOG performance status = 2, age ≥ 70, or prior pelvic radiation) and Arm B: OXAL 85 d1 + LV 200/5FU 400 bolus + 600 as a 22 hour infusion d1, 2 q2w. Final analysis was scheduled after 405 deaths to have 82% power to detect non-equivalence at a hazard ratio of 1.25. Results: 491 pts were randomized to Rx between 10/99 to12/03 (245-A, 246-B). 289 pts (59%) failed previous 5FU for metastatic CRC. 82% of pts have died. 220 pts (45%) received protocol mandated 3rd line therapy (A-57%, B-43%). Efficacy results (including OS, time to progression (TTP), and response rate (RR)) and common grade 3+ toxicities on initial Rx are shown in the table below. 16 pts died < 60 days of study entry (A-5%, B-2%, p = 0.12). 2nd line Rx with CPT-11 was associated with more grade ≥ 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 had more neutropenia and parasthesias. Conclusions: In pts failing prior 5FU Rx for CRC, OS is not significantly different based on whether 2nd line Rx begins with either CPT-11 or FOLFOX4 (HR=1.04, 95% CI 0.9–1.3). 2nd line Rx with FOLFOX4 produces a higher RR and a trend toward longer TTP. Both arms had notable OS in pts who had failed 1st line 5FU Rx. Supported by NIH Grant CA25224 and Sanofi-Synthelabo. Efficacy & Toxicity (≥ Grade 3), by Initial Rx
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16_suppl) , 3506
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU
3506 Background: Single agent CPT-11 is indicated as standard treatment (Rx) for pts with CRC who failed prior 5FU based Rx. FOLFOX4 is active as 1st and 2nd line Rx of CRC. The primary goal of this trial was to determine whether overall survival (OS) of pts treated with 2nd line CPT-11 (Arm A) was equivalent to Rx with 2nd line FOLFOX4 (Arm B). Pts were to cross-over to the other Rx after 2nd line failure. Methods: Eligible pts had failed one prior 5FU based Rx, either for metastatic disease or ≤ 6 months of adjuvant 5FU Rx. Initial protocol Rx (doses in mg/m2) for Arm A: CPT-11 350 d1 q3w (300 for ECOG performance status = 2, age ≥ 70, or prior pelvic radiation) and Arm B: OXAL 85 d1 + LV 200/5FU 400 bolus + 600 as a 22 hour infusion d1, 2 q2w. Final analysis was scheduled after 405 deaths to have 82% power to detect non-equivalence at a hazard ratio of 1.25. Results: 491 pts were randomized to Rx between 10/99 to12/03 (245-A, 246-B). 289 pts (59%) failed previous 5FU for metastatic CRC. 82% of pts have died. 220 pts (45%) received protocol mandated 3rd line therapy (A-57%, B-43%). Efficacy results (including OS, time to progression (TTP), and response rate (RR)) and common grade 3+ toxicities on initial Rx are shown in the table below. 16 pts died < 60 days of study entry (A-5%, B-2%, p = 0.12). 2nd line Rx with CPT-11 was associated with more grade ≥ 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 had more neutropenia and parasthesias. Conclusions: In pts failing prior 5FU Rx for CRC, OS is not significantly different based on whether 2nd line Rx begins with either CPT-11 or FOLFOX4 (HR=1.04, 95% CI 0.9–1.3). 2nd line Rx with FOLFOX4 produces a higher RR and a trend toward longer TTP. Both arms had notable OS in pts who had failed 1st line 5FU Rx. Supported by NIH Grant CA25224 and Sanofi-Synthelabo. Efficacy & Toxicity (≥ Grade 3), by Initial Rx
- 1 February 2002
- Published by Springer Nature in Quality of Life Research
- Vol. 11 (1) , 37-45
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot
One of the challenges of interpreting a Quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) analysis is examining the sensitivity of conclusions that may be drawn to varying...
- 1 February 2002
- Published by Springer Nature in Quality of Life Research
- Vol. 11 (1) , 37-45
A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot
One of the challenges of interpreting a Quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) analysis is examining the sensitivity of conclusions that may be drawn to varying...